News | May 07, 2026
Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity
Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility
Neuland Laboratories reported an uptick in peptide-related engagements from Japanese companies, particularly at the preclinical and early clinical stages
CDSCO-approved therapy enters India’s fast-growing post-patent GLP-1 market with fully integrated API, formulation and pen manufacturing
The first of four planned modules at the new plant is expected to come online by summer 2026
The new LEED Gold-certified building will serve as CordenPharma Colorado’s sole tenant
Biocon will be responsible for supplying Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, Middle East and Central Asia
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated
